AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
Check out details of Astrazeneca Ovarian Cancer Drug, Lynparza which in a phase 3 trial has been demonstrated to have improved survival of patients treated with Lynparza Ovarian Cancer Tablets.
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for patients with germline BRCA-mutations (gBRCA). This breakthrough offers new hope for patients with relapsed disease who have previously not responded to platinum-based chemotherapy. Breakthrough in Ovarian Cancer Treatment The trial […]